This is really good news...working with a major Pharma and an eminent researcher. Also noticed this line near the end...
The IONIC-1 study is an investigator-initiated study and will have no major impact on the Company’s R&D costs with a financial contribution being limited largely to the provision of Veyonda®.
Well..... that must mean someone else is paying for a chunk of it. So more good news.
Ann: Veyonda To Be Tested In Combination With Opdivo In Trial, page-3
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50000 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 66800 | 1 |
View Market Depth
| Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |